Acura Pharmaceuticals, Inc. is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products.
Our LIMITX Technology is intended to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested.
Our LIMITX Technology is intended to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested.
Services
Acura is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing the Company's proprietary LIMITX, IMPEDE and AVERSION Technology platforms. Intravenous injection by forming a viscous gelatinous mixture when tablets and capsules are dissolved in solvents suitable for injection.
AVERSION Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features and benefits for orally administered pharmaceutical drug products. Intravenous injection by forming a viscous gelatinous mixture when tablets and capsules are dissolved in solvents suitable for injection; and More.
LIMITX Technology is intended to mitigate the risks associated with intentional or overdose. LTX-03, an immediate-release hydrocodone bitartrate with acetaminophen tablet, is our lead LIMITX development program. Previously, we have run three exploratory human pharmacokinetic studies and two animal studies.
OXAYDO represents the first immediate-release oxycodone product approved by the FDA that applies Acura's AVERSION Technology. AVERSION is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering. Acura has developed several other tamper-resistant opioid products using AVERSION Technology.
Acura actively pursues patents and trademark protection for our business interests. In addition to our issued U.S. patents, we have filed multiple U.S. patent applications and international patent applications relating to compositions containing abusable active pharmaceutical ingredients as well as applications covering our IMPEDE and LIMITX Technologies.
Reviews
Be the first to review Acura Pharmaceutical Technolgies.
Write a Review